Kopytko Patrycja, Piotrowska Katarzyna, Janisiak Joanna, Tarnowski Maciej
Department of Physiology, Pomeranian Medical University in Szczecin, al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland.
Int J Mol Sci. 2021 Mar 11;22(6):2828. doi: 10.3390/ijms22062828.
Garcinol extracted from fruit peel and leaves is a polyisoprenylated benzophenone. In traditional medicine it was used for its antioxidant and anti-inflammatory properties. Several studies have shown anti-cancer properties of garcinol in cancer cell lines and experimental animal models. Garcinol action in cancer cells is based on its antioxidant and anti-inflammatory properties, but also on its potency to inhibit histone acetyltransferases (HATs). Recent studies indicate that garcinol may also deregulate expression of miRNAs involved in tumour development and progression. This paper focuses on the latest research concerning garcinol as a HAT inhibitor and miRNA deregulator in the development and progression of various cancers. Garcinol may be considered as a candidate for next generation epigenetic drugs, but further studies are needed to establish the precise toxicity, dosages, routes of administration, and safety for patients.
从果皮和树叶中提取的藤黄脂是一种多异戊二烯化二苯甲酮。在传统医学中，它因其抗氧化和抗炎特性而被使用。多项研究已表明藤黄脂在癌细胞系和实验动物模型中具有抗癌特性。藤黄脂在癌细胞中的作用基于其抗氧化和抗炎特性，还基于其抑制组蛋白乙酰转移酶（HATs）的能力。最近的研究表明，藤黄脂还可能使参与肿瘤发生和发展的微小RNA（miRNA）的表达失调。本文重点关注藤黄脂作为HAT抑制剂和miRNA失调调节剂在各种癌症发生和发展中的最新研究。藤黄脂可被视为下一代表观遗传药物的候选物，但需要进一步研究以确定其确切的毒性、剂量、给药途径以及对患者的安全性。
